Navigation Links
Takeda and Zinfandel Pharmaceuticals Initiate Phase 3 TOMMORROW Trial of AD-4833 for the Delay of Onset of Mild Cognitive Impairment Due to Alzheimer's Disease in Subjects Selected Using a Genetic-Based Biomarker Risk Assignment Algorithm
Date:8/26/2013

OSAKA, Japan and DURHAM, N.C., Aug. 26, 2013 /PRNewswire/ -- Takeda Pharmaceutical Company Limited ("Takeda") and its partner, Zinfandel Pharmaceuticals, Inc. ("Zinfandel"), today announced the initiation of TOMMORROW, a global Phase 3 clinical trial investigating a genetic-based biomarker risk assignment algorithm (risk assignment algorithm) to predict risk of mild cognitive impairment (MCI) due to Alzheimer's disease (AD) within a five year period and to evaluate the efficacy of the investigational low dose pioglitazone (designated AD-4833 for this use) in delaying the onset of MCI due to AD in cognitively normal individuals at high risk as determined by the risk assignment algorithm.

The risk assignment algorithm is comprised of apolipoprotein E (APOE) and TOMM40 genotypes and age. Age and APOE genotype have previously been shown to indicate elevated risk of AD. The addition of TOMM40 is hypothesized to further refine the risk determination.

"To date, there have been a number of avenues investigated with the goal of altering the course of Alzheimer's disease but results have been unsuccessful," said Allen Roses, M.D., Chief Executive Officer, Zinfandel. "This is why the TOMMORROW trial is important. The potential to identify an individual's risk for developing MCI due to AD warrants further investigation."

AD is a devastating disease and diagnoses are increasing as the world's population ages. Currently 35.6 million people worldwide are living with some form of dementia. Studies show that individuals with MCI are at an increased risk of developing AD or another dementia with conversion rates of approximately 15 percent per year.

"AD-4833 is a member of a class of drugs known as PPAR (peroxisome proliferator-activated receptor)-gamma agonists which available data show may have a beneficial role in delaying symptoms of MCI due to AD," noted '/>"/>

SOURCE Takeda Pharmaceutical Company Limited
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Takeda Launches New Subsidiary in Peru
2. Data Published in the New England Journal of Medicine for Vedolizumab, an Investigational New Drug from Takeda for Moderately to Severely Active Ulcerative Colitis and Crohns Disease
3. Among New Agents Entering the Unipolar Depression Market Over the Next Decade, Lundbeck/Takeda Pharmaceuticals Brintellix Has Blockbuster Potential
4. Takeda Submits Biologics License Application for a New Investigational Drug Vedolizumab, in Moderately to Severely Active Crohns Disease and Ulcerative Colitis in the United States
5. Takeda Type 2 Diabetes Therapies, NESINA (alogliptin) and Fixed-Dose Combinations KAZANO (alogliptin and metformin HCl) and OSENI (alogliptin and pioglitazone), Are Now Available in Pharmacies in the United States
6. AGA Research Foundation Announces Endowment Gift from Takeda Pharmaceuticals U.S.A., Inc. to Support Gastroenterology Research
7. Takeda to Acquire Inviragen, Inc.
8. Takeda Responds to Verdict in Diabetes Drug Case
9. Takeda Launches New Subsidiary in Ecuador
10. Takeda lanza nueva subsidiaria en Ecuador
11. Scripps Research Institute and Takeda Pharmaceuticals Announce Expanded Research Collaboration
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/28/2015)... , July 28, 2015 /PRNewswire/ - ESSA Pharma Inc. ("ESSA" or ... that it has received final approval for its common shares ... Exchange (the "TSX"). The Company,s common shares will commence trading ... under the trading symbol ,EPI,.  Concurrently, ESSA,s common shares will ... About ESSA Pharma Inc. ESSA Pharma is a ...
(Date:7/28/2015)... 2015 According to a new market ... Formulation), Therapeutic (Hormonal, Oncology), Usage Pattern (Curative Care, Immunization), Administration ... to 2020", published by MarketsandMarkets, the European Injectable Drug Delivery ... $114.7 Billion in 2015, growing at a CAGR of 12.6% ... 230 market data T ables and ...
(Date:7/27/2015)... and PARIS , July ...  and Sanofi have entered into a new global ... treatments in the emerging field of immuno-oncology. As part ... a programmed cell death protein 1 (PD-1) inhibitor currently ... trials in 2016 with new therapeutic candidates based on ...
Breaking Medicine Technology:ESSA Pharma Inc. to Commence Trading on the Toronto Stock Exchange 2ESSA Pharma Inc. to Commence Trading on the Toronto Stock Exchange 3European Injectable Drug Delivery Market Worth $207.3 Billion by 2020 2European Injectable Drug Delivery Market Worth $207.3 Billion by 2020 3European Injectable Drug Delivery Market Worth $207.3 Billion by 2020 4Regeneron and Sanofi Launch Major New Immuno-Oncology Collaboration 2Regeneron and Sanofi Launch Major New Immuno-Oncology Collaboration 3Regeneron and Sanofi Launch Major New Immuno-Oncology Collaboration 4Regeneron and Sanofi Launch Major New Immuno-Oncology Collaboration 5Regeneron and Sanofi Launch Major New Immuno-Oncology Collaboration 6Regeneron and Sanofi Launch Major New Immuno-Oncology Collaboration 7Regeneron and Sanofi Launch Major New Immuno-Oncology Collaboration 8
(Date:7/28/2015)... ... July 28, 2015 , ... ... has authorized the Company, from time to time and depending on market conditions, ... up to $25 million. Repurchases will be made in open market or privately ...
(Date:7/28/2015)... (PRWEB) , ... July 28, 2015 , ... ... services to include a proprietary, web based clinical knowledge system, called “Referral Guidance.” ... evidence based. It provides physicians who are anticipating making a subspecialty referral ...
(Date:7/28/2015)... , ... July 28, 2015 , ... Fertility specialist ... as a “Top Doctor 2015” by Atlanta Magazine. In Atlanta Magazine's annual Top Doctors ... hundreds of her esteemed colleagues and peers in the metro area as one of ...
(Date:7/28/2015)... ... 28, 2015 , ... A new study published by HealthDay News on June ... light on a possible new treatment option for people living with fibromyalgia – hyperbaric ... at least five per week, patients experienced a significant decrease in pain, fatigue, and ...
(Date:7/28/2015)... CA (PRWEB) , ... July 28, 2015 , ... ... of Acute Coronary Syndromes (ACS-Heart Attack, Sudden Death, or Angina), many of whom ... cardiology is the identification of individuals with active yet undetected sub-clinical disease, who ...
Breaking Medicine News(10 mins):Health News:Safeguard Scientifics Board of Directors Authorizes up to $25 Million Share Repurchase Program 2Health News:Safeguard Scientifics Board of Directors Authorizes up to $25 Million Share Repurchase Program 3Health News:Introducing Care to Care’s New Web Based “Referral Guidance” Program 2Health News:Atlanta Fertility Specialist Named Top Doctor in Atlanta Magazine 2Health News:Atlanta Fertility Specialist Named Top Doctor in Atlanta Magazine 3Health News:Recovery Specialists Discuss How Oxygen Therapy Can Ease Fibromyalgia 2Health News:Recovery Specialists Discuss How Oxygen Therapy Can Ease Fibromyalgia 3Health News:Utility of a novel coronary artery disease biomarker algorithm in modifying physician adherence to guideline therapy presented at 20th World Congress on Heart Disease 2
... lead to cognitive problems , , FRIDAY, Dec. 19 (HealthDay ... matter in a fetus, frontal and occipital lobes, which ... processing. The finding may help explain problems seen in ... says. , "The brain,s white matter is made up ...
... ultrasound device, developed by a Cornell graduate student, fits in ... punch to stabilize a gunshot wound or deliver drugs to ... called a transducer, and it creates sound waves so strong ... steam., Tinkering in his Olin Hall lab, George K. Lewis, ...
... hold the secret to eradicating malaria or schistosomiasis? ... is utilizing the combination of algorithms and models ... in the fight against infectious diseases. , Professor ... and analyze symptoms, treatment outcomes and environmental conditions ...
... with thoughts of getting in shape and improving our health, yet without ... fall by the wayside rather quickly. With a team approach, the ... tips to ensure success for a new and improved you in the ... ...
... program during holidays and economic challenges , ... ... provider of medical information and retail products understands the tough ... said "with the economy in shambles and millions of people ...
... the largest grant in its history: $24.4 million from ... cultural disparities in oral health. , The seven-year ... of Dental and Craniofacial Research, will enable the UCSF ... CAN DO) to launch new programs in preventing early ...
Cached Medicine News:Health News:Moms-to-Be Who Drink May Damage Fetus' White Matter 2Health News:Groundbreaking, inexpensive, pocket-sized ultrasound device can help treat cancer, relieve arthritis 2Health News:Case Western Reserve professor helps control infectious diseases with models and math 2Health News:Case Western Reserve professor helps control infectious diseases with models and math 3Health News:Case Western Reserve professor helps control infectious diseases with models and math 4Health News:Health Tips for the New Year; Patience and Persistence will Payoff; Key Advice from the Wellness Team at D.I.S.C. Sports and Spine Center 2Health News:Health Tips for the New Year; Patience and Persistence will Payoff; Key Advice from the Wellness Team at D.I.S.C. Sports and Spine Center 3Health News:Health Tips for the New Year; Patience and Persistence will Payoff; Key Advice from the Wellness Team at D.I.S.C. Sports and Spine Center 4Health News:Health Tips for the New Year; Patience and Persistence will Payoff; Key Advice from the Wellness Team at D.I.S.C. Sports and Spine Center 5Health News:Health Tips for the New Year; Patience and Persistence will Payoff; Key Advice from the Wellness Team at D.I.S.C. Sports and Spine Center 6Health News:UCSF receives $24.4 million to fight early childhood cavities 2
EnTrust family of ICDs provides a suite of features for total AT/AF co-morbidity management, including diagnostics to detect when your patient develops AT/AF, and both termination and intervention th...
... a key participant in the area of ... decade. Previous Medtronic autotransfusion systems allowed clinicians ... well as to determine requirements for a ... (PRP) for a small amount of autologous ...
... SJM Pericardial Patch with EnCap technology ... vessel reconstruction/repair and for pericardial closure. ... offers surgeons durability and flexibility, plus ... patches. Equally important in a tissue ...
... triaxial catheter design and ergonomic handle ... proprietary radiopaque Nitinol markers on the ... stent enhance visibility. Corrugated ring design ... the nested ring pattern minimizes stent ...
Medicine Products: